Canagliflozin (** Invokana (primary brand name); also available as generic canagliflozin **)
Other Medications
Description
Canagliflozin is primarily used for the treatment of type 2 diabetes and not in colorectal cancer. There are no clinical data supporting its use in CCR as an antineoplastic agent; it remains investigational or off-label outside its approved indications.
Mechanism of Action
Canagliflozin is an SGLT2 inhibitor that works by blocking the reabsorption of glucose in the proximal renal tubules, leading to increased urinary glucose excretion.
Side Effects
Hypoglycemia when used with insulin or sulfonylureas; urinary tract infections; genital mycotic infections; acute kidney injury; bone fractures; increased LDL cholesterol; hypersensitivity reactions
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07076823
Phase 1
Recruiting
Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer
China
NCT07703163
Phase 1
Not yet recruiting
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Quick Info
| Brand Name | ** Invokana (primary brand name); also available as generic canagliflozin ** |
| Category | Other Medications |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS other indication |
| Clinical Trials | 2 |
Related Medications
Uracil
Other Medications
789 trials
Leucovorin
Other Medications
651 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.